Dianthus Therapeutics, Inc. /DE/ Quarterly Operating Income (Loss) in USD from Q1 2017 to Q3 2024

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Dianthus Therapeutics, Inc. /DE/ quarterly/annual Operating Income (Loss) history and growth rate from Q1 2017 to Q3 2024.
  • Dianthus Therapeutics, Inc. /DE/ Operating Income (Loss) for the quarter ending September 30, 2024 was -$29.9M, a 89.7% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ Operating Income (Loss) for the twelve months ending September 30, 2024 was -$82.9M, a 462% decline year-over-year.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2023 was -$48.2M, a 62.2% decline from 2022.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2022 was -$29.7M, a 127% decline from 2021.
  • Dianthus Therapeutics, Inc. /DE/ annual Operating Income (Loss) for 2021 was -$13.1M, a 83.4% increase from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 -$82.9M -$29.9M -$14.1M -89.7% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-07
Q2 2024 -$68.8M -$22.2M -$10.4M -88.6% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-08
Q1 2024 -$58.3M -$17.8M -$10.2M -132% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 -$48.2M -$13M -$33.4M -163% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-21
Q3 2023 -$14.8M -$15.8M -$7.51M -90.9% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-07
Q2 2023 -$7.25M -$11.8M +$6.31M +34.9% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-08
Q1 2023 -$13.6M -$7.68M +$16.2M +67.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 -$29.7M $20.5M -$21M -50.6% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-21
Q3 2022 -$8.71M -$8.25M +$9.99M +54.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 -$18.7M -$18.1M -$473K -2.69% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 -$18.2M -$23.8M -$5.14M -27.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 -$13.1M $41.5M +$60.5M Oct 1, 2021 Dec 31, 2021 8-K 2023-12-21
Q3 2021 -$73.6M -$18.2M +$136K +0.74% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 -$73.8M -$17.6M +$2.4M +12% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-04
Q1 2021 -$76.2M -$18.7M +$2.55M +12% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-16
Q4 2020 -$78.7M -$19.1M +$5.57M +22.6% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-08
Q3 2020 -$84.3M -$18.4M +$4.26M +18.8% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 -$88.5M -$20M -$674K -3.49% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 -$87.9M -$21.2M -$4.89M -29.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 -$83M -$24.6M -$6.71M -37.4% Oct 1, 2019 Dec 31, 2019 10-K 2020-03-03
Q3 2019 -$76.3M -$22.6M -$5.94M -35.6% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 -$70.3M -$19.3M -$5.31M -37.9% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-06
Q1 2019 -$65M -$16.4M -$5.04M -44.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 -$60M -$17.9M -$9.76M -119% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-03
Q3 2018 -$50.2M -$16.7M -$9.69M -138% Jul 1, 2018 Sep 30, 2018 10-K 2020-03-03
Q2 2018 -$40.5M -$14M +$1.71M +10.8% Apr 1, 2018 Jun 30, 2018 10-K 2020-03-03
Q1 2018 -$42.2M -$11.3M -$6.5M -135% Jan 1, 2018 Mar 31, 2018 10-K 2020-03-03
Q4 2017 -$35.7M -$8.17M Oct 1, 2017 Dec 31, 2017 10-K 2019-03-19
Q3 2017 -$7.02M Jul 1, 2017 Sep 30, 2017 10-K 2019-03-19
Q2 2017 -$15.7M Apr 1, 2017 Jun 30, 2017 10-K 2019-03-19
Q1 2017 -$4.81M Jan 1, 2017 Mar 31, 2017 10-K 2019-03-19
* An asterisk sign (*) next to the value indicates that the value is likely invalid.